Nanobiotix (NASDAQ:NBTX) Shares Down 8.4% - Should You Sell?

Key Points

• Nanobiotix shares fell 8.4% to $41.35, with trading volume about 43% above the average session level.
• Analyst sentiment remains mixed but leans positive: four analysts rate the stock Buy, one Hold and one Sell, producing a “Moderate Buy” consensus. However, the $37.33 consensus price target is below the current share price.
• Nanobiotix is a clinical-stage biotechnology company developing NBTXR3, a nanoparticle-based radioenhancer for cancer treatment; the product has received European CE Mark approval for soft tissue sarcoma. Institutional investors own 38.81% of the stock.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares traded down 8.4% during trading on Friday . The stock traded as low as $41.00 and last traded at $41.35. Approximately 120,522 shares changed hands during mid-day trading, an increase of 43% from the average session volume of 84,377 shares. The stock had previously closed at $45.16.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NBTX shares. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research report on Monday, May 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Nanobiotix in a report on Friday, July 17th. UBS Group lifted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the company a "neutral" rating in a research note on Friday, May 1st. Finally, Leerink Partners upped their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an "outperform" rating in a report on Thursday, June 4th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.33.

Nanobiotix Trading Down 8.7%

The business has a fifty day moving average of $39.15 and a 200-day moving average of $36.07.

Institutional Trading of Nanobiotix

A number of large investors have recently added to or reduced their stakes in NBTX. Royal Bank of Canada grew its position in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after buying an additional 2,500 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Nanobiotix during the 4th quarter valued at $220,000. Finally, Millennium Management LLC acquired a new stake in shares of Nanobiotix during the 4th quarter valued at $390,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source